149 related articles for article (PubMed ID: 32436062)
1. Intracellular localization of beta-catenin expression plays a possible prognostic role on the outcome of hepatoblastoma patients.
Celtik U; Dokumcu Z; Divarci E; Guler E; Ataseven E; Nart D; Yilmaz F; Celik A; Ergün O
Pediatr Surg Int; 2020 Jul; 36(7):817-825. PubMed ID: 32436062
[TBL] [Abstract][Full Text] [Related]
2. HGF/c-Met related activation of β-catenin in hepatoblastoma.
Purcell R; Childs M; Maibach R; Miles C; Turner C; Zimmermann A; Sullivan M
J Exp Clin Cancer Res; 2011 Oct; 30(1):96. PubMed ID: 21992464
[TBL] [Abstract][Full Text] [Related]
3. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma.
Park WS; Oh RR; Park JY; Kim PJ; Shin MS; Lee JH; Kim HS; Lee SH; Kim SY; Park YG; An WG; Kim HS; Jang JJ; Yoo NJ; Lee JY
J Pathol; 2001 Apr; 193(4):483-90. PubMed ID: 11276007
[TBL] [Abstract][Full Text] [Related]
4. A novel tissue-based ß-catenin gene and immunohistochemical analysis to exclude familial adenomatous polyposis among children with hepatoblastoma tumors.
Dubbink HJ; Hollink IHIM; Avenca Valente C; Wang W; Liu P; Doukas M; van Noesel MM; Dinjens WNM; Wagner A; Smits R
Pediatr Blood Cancer; 2018 Jun; 65(6):e26991. PubMed ID: 29446530
[TBL] [Abstract][Full Text] [Related]
5. beta-Catenin and met deregulation in childhood Hepatoblastomas.
Ranganathan S; Tan X; Monga SP
Pediatr Dev Pathol; 2005; 8(4):435-47. PubMed ID: 16211454
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of beta-catenin in hepatoblastoma and its clinical significance.
Archana B; D'Cruze L; Nazneen S; Thanka J; Scott JX
J Cancer Res Ther; 2022; 18(3):677-680. PubMed ID: 35900540
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of beta-catenin in hepatoblastoma cells.
Ellerkamp V; Lieber J; Nagel C; Wenz J; Warmann SW; Fuchs J; Armeanu-Ebinger S
Pediatr Surg Int; 2013 Feb; 29(2):141-9. PubMed ID: 23266718
[TBL] [Abstract][Full Text] [Related]
8. Prognostic roles of pathology markers immunoexpression and clinical parameters in Hepatoblastoma.
Wu JF; Chang HH; Lu MY; Jou ST; Chang KC; Ni YH; Chang MH
J Biomed Sci; 2017 Aug; 24(1):62. PubMed ID: 28851352
[TBL] [Abstract][Full Text] [Related]
9. Wnt/β-catenin signaling as a useful therapeutic target in hepatoblastoma.
Sha YL; Liu S; Yan WW; Dong B
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31511432
[TBL] [Abstract][Full Text] [Related]
10. Elevated expression of Wnt antagonists is a common event in hepatoblastomas.
Koch A; Waha A; Hartmann W; Hrychyk A; Schüller U; Waha A; Wharton KA; Fuchs SY; von Schweinitz D; Pietsch T
Clin Cancer Res; 2005 Jun; 11(12):4295-304. PubMed ID: 15958610
[TBL] [Abstract][Full Text] [Related]
11. SOX7 modulates the progression of hepatoblastoma through the regulation of Wnt/β-catenin signaling pathway.
Ge J; Zheng Q; Qu H; Zhao Z; Xu Y; Wang H; Gao H; Zhan J
J Cancer Res Ther; 2022 Apr; 18(2):370-377. PubMed ID: 35645102
[TBL] [Abstract][Full Text] [Related]
12. Nur77 inhibition of β-catenin expression mediates Hepatoblastoma progression and enhances cisplatin's therapeutic effect.
Zhou J; Liu X; Yin H; Zhou Y; Xu Z; Zhou K; Li T; Fang Y; Shen Q
Gene; 2024 May; 908():148292. PubMed ID: 38369247
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors.
Yamaoka H; Ohtsu K; Sueda T; Yokoyama T; Hiyama E
Oncol Rep; 2006 Mar; 15(3):551-6. PubMed ID: 16465411
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma.
Jeng YM; Wu MZ; Mao TL; Chang MH; Hsu HC
Cancer Lett; 2000 Apr; 152(1):45-51. PubMed ID: 10754205
[TBL] [Abstract][Full Text] [Related]
15. GREB1 induced by Wnt signaling promotes development of hepatoblastoma by suppressing TGFβ signaling.
Matsumoto S; Yamamichi T; Shinzawa K; Kasahara Y; Nojima S; Kodama T; Obika S; Takehara T; Morii E; Okuyama H; Kikuchi A
Nat Commun; 2019 Aug; 10(1):3882. PubMed ID: 31462641
[TBL] [Abstract][Full Text] [Related]
16. β-Catenin mutations as determinants of hepatoblastoma phenotypes in mice.
Zhang W; Meyfeldt J; Wang H; Kulkarni S; Lu J; Mandel JA; Marburger B; Liu Y; Gorka JE; Ranganathan S; Prochownik EV
J Biol Chem; 2019 Nov; 294(46):17524-17542. PubMed ID: 31597698
[TBL] [Abstract][Full Text] [Related]
17. Relationship of β-catenin and postchemotherapy histopathologic changes with overall survival in patients with hepatoblastoma.
Gupta K; Rane S; Das A; Marwaha RK; Menon P; Rao KL
J Pediatr Hematol Oncol; 2012 Nov; 34(8):e320-8. PubMed ID: 22735888
[TBL] [Abstract][Full Text] [Related]
18. Complementary roles of β-catenin and glutamine synthetase immunostaining in diagnosis of chemotherapy-treated and untreated hepatoblastoma.
Huang WJ; Tsai JH; Jeng YM
J Formos Med Assoc; 2017 Jul; 116(7):549-553. PubMed ID: 28277286
[TBL] [Abstract][Full Text] [Related]
19. Wnt signaling and hepatocarcinogenesis: the hepatoblastoma model.
Armengol C; Cairo S; Fabre M; Buendia MA
Int J Biochem Cell Biol; 2011 Feb; 43(2):265-70. PubMed ID: 19646548
[TBL] [Abstract][Full Text] [Related]
20. Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam.
Anna CH; Sills RC; Foley JF; Stockton PS; Ton TV; Devereux TR
Cancer Res; 2000 Jun; 60(11):2864-8. PubMed ID: 10850429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
